Journals / Göztepe Tıp Dergisi / 2009 / Cilt: 24 - Sayı: 4

Hepatocellular carcinoma revealed by iliac bone metastasis: Case report

Sakroiliak kemik metastazı ile tanısı konulan hepatosellüler karsinom

Pages
204–208
Publication Date
2022-10-17
DOI
—
🏛️Bibliographic metadata and full text access for this article are provided via DergiPark.
DergiPark Record ↗
✨

AI Summary & Key Takeaways

AI Insight
⚡ TL;DR(Too Long; Didn't Read)

We present a case of HCC confirmed by the biopsy from the iliac bone which is a rare metastatic region of HCC.

📌 3 Key Takeaways

🎯
Objective & Hypothesis:Hepatocellular carcinoma (HCC) is the most common primary malignant tumor in liver and it is one of the most common cancers worldwide.
📊
Key Findings & Data:The most important risk factors for HCC are cirrhosis, viral hepatitis, alcohol abuse and metabolic liver disease.
💡
Conclusion & Impact:We present a case of HCC confirmed by the biopsy from the iliac bone which is a rare metastatic region of HCC.
🔬Design:Research Article
📍Scope:Comprehensive Sample
⚙️Variables:Domain Parameters

Abstract

Hepatocellular carcinoma (HCC) is the most common primary malignant tumor in liver and it is one of the most common cancers worldwide. The most important risk factors for HCC are cirrhosis, viral hepatitis, alcohol abuse and metabolic liver disease. HCC presents with hepatic involvement in majority and as metastatic disease in minority of patients. HCC commonly makes metastases to lungs, lymph nodes, adrenal gland, whereas bone involvement is rare. Bone metastases of HCC, usually do not give symptom unless any pathological fracture happens or before they reach great dimensions. We present a case of HCC confirmed by the biopsy from the iliac bone which is a rare metastatic region of HCC.

Özet

Hepatosellüler karsinoma (HSK) karaciğerin en yaygın primer malign tümörüdür ve tüm dünyada en sık görülen kanserlerden biridir. HSK’un en önemli risk faktörleri siroz, viral hepatitler, alkol kullanımı ve metabolik karaciğer hastalıklarıdır. HSK olguların çoğunda hepatik tutulum ile kendini gösterirken, vakaların çok azında metastatik hastalık izlenir. HSK en çok akciğer, lenf nodu, adrenal glanda metastaz yaparken, kemik tutulumu nadirdir. HSK’nın kemik metastazları genellikle büyük boyutlara ulaşmadan veya patolojik fraktür oluşturmadan semptom vermezler. Bu yazıda nadir metastaz bölgesi olan iliak kemikten yapılan biyopsi ile tanı konulan HSK’lı bir olgu sunulmuştur.

🔖

Cite This Article

YORULMAZ, E., KIZILGÜL, M., TUNCER, İ., ZEMHERİ, E., AYAZ, T., ÖZÇELİK, S. (2022). Hepatocellular carcinoma revealed by iliac bone metastasis: Case report. Göztepe Tıp Dergisi, Cilt: 24 - Sayı: 4, 204–208. https://ajindex.com/articles/526193

📄 Full Text PDF Viewer

📄

PDF görüntüleyici hazırlanıyor...

References (17)

  1. Bosch FX, Ribes J, Borras J. Epidemiology of primary liver cancer. Semin Liver Dis 1999;19:271-285
  2. Parkin DM, Bray F, Ferlay J, et al. Estimating the world cancer burden: GLOBOCAN 2000. Int J Cancer 2001;94:153-56
  3. Özdoğan OC. Klinik Gastroenteroloji ve Hepatoloji. Tözün N, Şimşek H, Özkan H ve ark. (editörler). Klinik Gastroenteroloji ve Hepatoloji 1. baskı, MN Medikal ve Nobel Tıp Kitap Sarayı, Ankara 2007: 599-603
  4. Bruix J, Llovet JM. Prognostic prediction and treatment strategy in hepatocellular carcinoma. Hepatology 2002;35:519-24
  5. Yuki K, Hirohashi S, Sakamoto M, et al. Growth and spread of hepatocellular carcinoma. A review of 240 autopsy cases. Cancer 1990;66:2174
  6. Kew MC. Hepatic Tumors and Cysts. In: Feldman M, Frıedman LS, Brandt LJ (eds). Gastrointestinal and Liver Disease. 8th Ed., Saunders, Philadelphia, 2006: 2007-2033
  7. Burdette W. Hepatocellular carcinoma. In: Schiff L (ed). Diseases of the liver. 4th ed. Philadelphia: J.B. Lippincott, 1975: 1051-1074
  8. Linder GT, Crook JN, Cohn I. Primary liver carcinoma. Cancer 1974;33:1624-1629
  9. Bosch FX, Ribes J, Diaz M, et al. Primary liver cancer: worldwide incidence and trends. Gastroenterology 2004;127:5-16
  10. Fattovich G, Stroffolini T, Zagni I, et al. Hepatocellular carcinoma in cirrhosis: incidence and risk factors. Gastroenterology 2004;127:35-50
  11. Beasley RP, Hwang LY, Lin CC, et al. Hepatocellular carcinoma and hepatitis B virus: a prospective study of 22 707 men in Taiwan. Lancet 1981;2:1129-33
  12. Fattovich G, Guistina G, Schalm SW, et al. Occurrence of hepatocellular carcinoma and decompensation in Western European patients with cirrhosis type B: The EUROHEP Study Group on Hepatitis B Virus and Cirrhosis. Hepatology 1995;21:77-82
  13. Bruix J, Barrera JM, Calvet X, et al. Prevalence of antibodies to hepatitis C virus in Spanish patients with hepatocellular carcinoma and hepatic cirrhosis. Lancet 1989;2:1004-06
  14. Tsukuma H, Hiyama T, Tanaka S, et al. Risk factors for hepatocellular carcinoma among patients with chronic liver disease. N Eng J Med 1993;328:1797-801
  15. Bressac B, Kew M, Wands J, et al. Selective G to T mutations of p53 gene in hepatocellular carcinoma from southern Africa. Nature 1991;350:429-431
  16. Ziyaettin Durakoğlu. Karaciğerde kütle Lezyonlar. Danalıoğlu A, Beşışık F (çeviri editörleri). Mayo Klinik Gastroenteroloji ve Hepatoloji. 1. baskı, İstanbul Medikal Yayıncılık, İstanbul, 2005: 327-334
  17. Patton RB, Horn RC. Primary liver ca